search
Back to results

Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study (DIET)

Primary Purpose

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Dietary Intervention
Dietary Intervention
Quality-of-Life Assessment
Questionnaire Administration
Sponsored by
M.D. Anderson Cancer Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Clinical Stage III Cutaneous Melanoma AJCC v8

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age ≥ 18 years old.
  2. Body mass index (BMI) 18.5-40 kg/m^2
  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  4. English-speaking
  5. Self-reported willingness to exclusively eat the provided diets
  6. Self-reported willingness to comply with scheduled visits, undergo venipuncture, and provide stool samples
  7. Cohort-specific:

Unresectable:

i. Histologically confirmed unresectable stage III or stage IV melanoma ii. Currently receiving therapy with standard of care anti-PD1 immunotherapy. Initial induction with anti-CTLA4 and anti-PD1 is allowed iii. Stable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as best response while on anti-PD1 >= 6 months for metastatic melanoma with plan to continue anti-PD1 iv. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST version [v]1.1; i.e., defined as at least 1 lesion that can be accurately measured in at least 1 dimension [longest diameter to be recorded] with a minimum size of >= 10 mm by computerized tomography [CT] scan or caliper measurement on clinical exam)

  1. Participants must have at least one lesion amenable to biopsy that has not been previously irradiated
  2. Participants must be willing to undergo a newly-obtained core needle or incisional biopsy at baseline. Fine needle aspiration is not acceptable

Adjuvant:

i. Resected stage II-IV melanoma with planned initiation of adjuvant anti-PD1 +/- anti-CTLA4

Neoadjuvant:

i. Histologically confirmed stage III/IV melanoma with planned initiation of neoadjuvant anti-PD1 + anti-CTLA4

1. Participants must be willing to undergo a newly-obtained core needle or incisional biopsy at baseline. Fine needle aspiration is not acceptable.

Exclusion Criteria:

  1. History of >= grade II colitis or diarrhea on immunotherapy or any ongoing colitis or diarrhea of any grade
  2. Unresolved >= grade III immune-related adverse event on immunotherapy (other than endocrinopathy requiring hormone replacement)
  3. History of active inflammatory bowel disease or major gastrointestinal surgery (not including appendectomy or cholecystectomy) within 3 months of enrollment or any history of total colectomy, or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e. restrictive procedures such as banding, are permitted).
  4. Medical contraindications to intervention diet as determined by the treating physician
  5. Self-reported major dietary restrictions related to the intervention
  6. Diagnosis of diabetes mellitus type I or type II that requires medical treatment or random glucose > 200 mg/dL
  7. Antibiotic use within 21 days of planned start of equilibration diet (self-reported and/or noted by the treating physician)
  8. Has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study intervention administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
  9. Regularly taking probiotics, fiber supplements, or any other medication or supplement that could affect study outcome as determined by the principal investigator and unable/unwilling to discontinue for the purpose of the study. These agents must be discontinued at least 14 days prior to start of diet
  10. Currently consuming an average estimated daily fiber intake exceeding 20 grams based on the results of the preliminary dietary assessment; vegetarian or vegan
  11. Current smoker or heavy drinker (defined as > 14 drinks per week) or current self reported illicit drug use
  12. Uncontrolled concurrent illness or infection or psychiatric illness/social situations that would limit compliance with study requirements
  13. Unable or unwilling to undergo study procedures
  14. Plan for travel during the study that would preclude adherence to prescribed diets

Sites / Locations

  • M D Anderson Cancer CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Arm I (isocaloric high-fiber diet)

Arm II (isocaloric diet)

Arm Description

Patients receive a whole foods diet that follows the recommended American Cancer Society guidelines but is higher in fiber for 11 weeks.

Patients receive a standard whole foods diet recommended by the American Cancer Society for 11 weeks.

Outcomes

Primary Outcome Measures

Change in the gut microbiome
Changes of alpha-diversity (e.g., Shannon index) and abundance/relative abundance of different taxon levels (e.g., genus, family), from baseline to end of intervention, will be estimated. The outcomes will be compared. between two arms using t-test or Mann-Whitney test. Linear mixed effects models will be used for assessing the longitudinal data. Similarity in microbiome community structure will be assessed using principal coordinate analysis (PCoA) and compared using multivariate analysis of variance (MANOVA).

Secondary Outcome Measures

Change in systemic and tumor immunity
Percent change in CD8 T cells using flow cytometry will be compared between two arms using t-test or Mann-Whitney test. Pearson or Spearman correlation coefficient will be used to assess the correlation between the outcome at baseline and end of intervention.
Change in metabolic profile
Change in relative concentration (ion intensity determined as area under the curve) measured by mass spectrometry-based analysis of blood and fecal specimens from baseline to end of intervention will be compared between two arms using t-test or Mann-Whitney test.
Change in quality of life (QOL)
Change in quality of life between baseline and end of intervention using a validated, 30 question scoring instrument (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Each question is scored in from 1 ("not at all") to 4 ("very much") in a Likert format. Linear mixed effects models will be used for assessing the longitudinal data. Pearson or Spearman correlation coefficient will be used to assess the correlation between measures for quality of life at baseline and end of intervention.
Incidence of adverse events
AEs attributed to diet as well as immune-related adverse events (irAEs) attributed to immunotherapy will be assessed using frequency counts and percentages.
Symptom profile
To assess gastrointestinal symptoms related to the dietary interventions, the GSRS-IBS will be used. The GSRS-IBS is a 13-item validated instrument with subscales for each item ranging from 0 ("no discomfort at all") to 7 ("very severe discomfort"). The gastrointestinal symptoms (GSRS-IBS) will be summarized using frequency counts and percentages.

Full Information

First Posted
October 16, 2020
Last Updated
April 5, 2023
Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT04645680
Brief Title
Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study
Acronym
DIET
Official Title
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 24, 2020 (Actual)
Primary Completion Date
February 1, 2024 (Anticipated)
Study Completion Date
February 1, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
M.D. Anderson Cancer Center
Collaborators
National Cancer Institute (NCI)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This phase II trial investigates the possible immune effects of two different diets targeting the gut microbiome in patients with stage III-IV melanoma that has been removed by surgery (resectable), has spread to other places in the body (metastatic), or is unable to be removed by surgery (unresectable), and who are being treated with the immunotherapy drugs pembrolizumab or nivolumab as part of their standard of care. Both diets are whole foods diets that meet the American Cancer Society recommendations for cancer patients, but they will vary in fiber content. The purpose of this trial is to learn about the effects of dietary interventions on the structure and function of the gut microbiome in patients with melanoma being treated with standard of care immunotherapy (pembrolizumab or nivolumab).
Detailed Description
PRIMARY OBJECTIVE: To establish the effects of dietary intervention on the structure and function of the gut microbiome. SECONDARY OBJECTIVES: Assess the effects of dietary intervention on gut metabolic output and systemic metabolism. Assess the effects of dietary intervention on systemic and tumor immunity Determine the safety (AEs) and tolerability (GSRS-IBS) of the dietary intervention Assess the rate of immune related adverse events in patients on immunotherapy receiving dietary interventions Determine the maximum daily fiber content that 70% of participants are able to tolerate Assess the adherence to the dietary interventions as defined by 70% of calories consumed over the duration of the study being derived from provided diets (as measured by food records) Assess the effects of dietary interventions on quality of life and other patient reported outcomes (PROs) EXPLORATORY OBJECTIVES: Assess the association of dietary interventions with clinical outcomes (objective response rate [ORR] and progression-free survival [PFS] rate in unresectable cohort and recurrence rate [RR] in adjuvant cohort). Explore predictors of biological response to dietary interventions. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I (ISOCALORIC HIGH-FIBER DIET): Patients receive a whole foods diet that follows the recommended American Cancer Society guidelines but is higher in fiber for 11 weeks. ARM II (ISOCALORIC CONTROL DIET): Patients receive a standard whole foods diet of recommended by the American Cancer Society for 11 weeks. After completion of study, patients are followed up at 12 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Unresectable Melanoma

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Masking Description
Participants will be blinded to their assigned diet throughout the intervention as will the investigators and research staff with the exception of the dietitian and the staff performing group assignment and data entry who will not have contact with participant
Allocation
Randomized
Enrollment
42 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm I (isocaloric high-fiber diet)
Arm Type
Experimental
Arm Description
Patients receive a whole foods diet that follows the recommended American Cancer Society guidelines but is higher in fiber for 11 weeks.
Arm Title
Arm II (isocaloric diet)
Arm Type
Active Comparator
Arm Description
Patients receive a standard whole foods diet recommended by the American Cancer Society for 11 weeks.
Intervention Type
Other
Intervention Name(s)
Dietary Intervention
Other Intervention Name(s)
Dietary Modification, intervention, dietary, Nutrition Intervention, Nutrition Interventions, Nutritional Interventions
Intervention Description
Consume isocaloric whole foods diet higher in fiber
Intervention Type
Other
Intervention Name(s)
Dietary Intervention
Other Intervention Name(s)
Dietary Modification, intervention, dietary, Nutrition Intervention, Nutrition Interventions, Nutritional Interventions
Intervention Description
Whole foods diet
Intervention Type
Other
Intervention Name(s)
Quality-of-Life Assessment
Other Intervention Name(s)
Quality of Life Assessment
Intervention Description
Ancillary studies
Intervention Type
Other
Intervention Name(s)
Questionnaire Administration
Intervention Description
Ancillary studies
Primary Outcome Measure Information:
Title
Change in the gut microbiome
Description
Changes of alpha-diversity (e.g., Shannon index) and abundance/relative abundance of different taxon levels (e.g., genus, family), from baseline to end of intervention, will be estimated. The outcomes will be compared. between two arms using t-test or Mann-Whitney test. Linear mixed effects models will be used for assessing the longitudinal data. Similarity in microbiome community structure will be assessed using principal coordinate analysis (PCoA) and compared using multivariate analysis of variance (MANOVA).
Time Frame
Baseline up to 11 weeks
Secondary Outcome Measure Information:
Title
Change in systemic and tumor immunity
Description
Percent change in CD8 T cells using flow cytometry will be compared between two arms using t-test or Mann-Whitney test. Pearson or Spearman correlation coefficient will be used to assess the correlation between the outcome at baseline and end of intervention.
Time Frame
Up to 12 weeks
Title
Change in metabolic profile
Description
Change in relative concentration (ion intensity determined as area under the curve) measured by mass spectrometry-based analysis of blood and fecal specimens from baseline to end of intervention will be compared between two arms using t-test or Mann-Whitney test.
Time Frame
Baseline up to 11 weeks
Title
Change in quality of life (QOL)
Description
Change in quality of life between baseline and end of intervention using a validated, 30 question scoring instrument (European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Each question is scored in from 1 ("not at all") to 4 ("very much") in a Likert format. Linear mixed effects models will be used for assessing the longitudinal data. Pearson or Spearman correlation coefficient will be used to assess the correlation between measures for quality of life at baseline and end of intervention.
Time Frame
Baseline up to 11 weeks
Title
Incidence of adverse events
Description
AEs attributed to diet as well as immune-related adverse events (irAEs) attributed to immunotherapy will be assessed using frequency counts and percentages.
Time Frame
Up to 12 weeks
Title
Symptom profile
Description
To assess gastrointestinal symptoms related to the dietary interventions, the GSRS-IBS will be used. The GSRS-IBS is a 13-item validated instrument with subscales for each item ranging from 0 ("no discomfort at all") to 7 ("very severe discomfort"). The gastrointestinal symptoms (GSRS-IBS) will be summarized using frequency counts and percentages.
Time Frame
Up to 12-week follow-up
Other Pre-specified Outcome Measures:
Title
Objective response rate (ORR) (unresectable cohort)
Description
Response will be assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. The ORR will be estimated along with 95% confidence interval, and compared between two diet groups using Chi-squared test or Fisher's exact test as appropriate.
Time Frame
At 12-week follow-up
Title
Progression-free survival (PFS) (unresectable cohort)
Description
Response will be assessed by RECIST 1.1. PFS will be assessed using Kaplan-Meier method and compared between two diet groups using log-rank test.
Time Frame
Up to 12-week follow-up
Title
Recurrence rate (RR) (adjuvant cohort)
Description
Response will be assessed by RECIST 1.1. The RR will be estimated along with 95% confidence interval, and compared between two diet groups using Chi-squared test or Fisher's exact test as appropriate.
Time Frame
Up to 12-week follow-up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years old. Body mass index (BMI) 18.5-40 kg/m^2 Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 English-speaking Self-reported willingness to exclusively eat the provided diets Self-reported willingness to comply with scheduled visits, undergo venipuncture, and provide stool samples Cohort-specific: Unresectable: i. Histologically confirmed unresectable stage III or stage IV melanoma ii. Currently receiving therapy with standard of care anti-PD1 immunotherapy. Initial induction with anti-CTLA4 and anti-PD1 is allowed iii. Stable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as best response while on anti-PD1 >= 6 months for metastatic melanoma with plan to continue anti-PD1 iv. Measurable disease as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST version [v]1.1; i.e., defined as at least 1 lesion that can be accurately measured in at least 1 dimension [longest diameter to be recorded] with a minimum size of >= 10 mm by computerized tomography [CT] scan or caliper measurement on clinical exam) Participants must have at least one lesion amenable to biopsy that has not been previously irradiated Participants must be willing to undergo a newly-obtained core needle or incisional biopsy at baseline. Fine needle aspiration is not acceptable Adjuvant: i. Resected stage II-IV melanoma with planned initiation of adjuvant anti-PD1 +/- anti-CTLA4 Neoadjuvant: i. Histologically confirmed stage III/IV melanoma with planned initiation of neoadjuvant anti-PD1 + anti-CTLA4 1. Participants must be willing to undergo a newly-obtained core needle or incisional biopsy at baseline. Fine needle aspiration is not acceptable. Exclusion Criteria: History of >= grade II colitis or diarrhea on immunotherapy or any ongoing colitis or diarrhea of any grade Unresolved >= grade III immune-related adverse event on immunotherapy (other than endocrinopathy requiring hormone replacement) History of active inflammatory bowel disease or major gastrointestinal surgery (not including appendectomy or cholecystectomy) within 3 months of enrollment or any history of total colectomy, or bariatric surgery (bariatric surgery which does not disrupt the gastrointestinal lumen, i.e. restrictive procedures such as banding, are permitted). Medical contraindications to intervention diet as determined by the treating physician Self-reported major dietary restrictions related to the intervention Diagnosis of diabetes mellitus type I or type II that requires medical treatment or random glucose > 200 mg/dL Antibiotic use within 21 days of planned start of equilibration diet (self-reported and/or noted by the treating physician) Has a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study intervention administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active autoimmune disease Regularly taking probiotics, fiber supplements, or any other medication or supplement that could affect study outcome as determined by the principal investigator and unable/unwilling to discontinue for the purpose of the study. These agents must be discontinued at least 14 days prior to start of diet Currently consuming an average estimated daily fiber intake exceeding 20 grams based on the results of the preliminary dietary assessment; vegetarian or vegan Current smoker or heavy drinker (defined as > 14 drinks per week) or current self reported illicit drug use Uncontrolled concurrent illness or infection or psychiatric illness/social situations that would limit compliance with study requirements Unable or unwilling to undergo study procedures Plan for travel during the study that would preclude adherence to prescribed diets
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jennifer McQuade
Phone
713-745-9947
Email
jmcquade@mdanderson.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jennifer McQuade
Organizational Affiliation
M.D. Anderson Cancer Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
M D Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jennifer McQuade
Phone
713-745-9947
Email
jmcquade@mdanderson.org
First Name & Middle Initial & Last Name & Degree
Jennifer McQuade

12. IPD Sharing Statement

Links:
URL
http://www.mdanderson.org
Description
MD Anderson Cancer Center

Learn more about this trial

Effect of Diet on the Immune System in Patients With Stage III-IV Melanoma Receiving Immunotherapy, DIET Study

We'll reach out to this number within 24 hrs